Skip to main content
Premium Trial:

Request an Annual Quote

At Galapagos, Small Molecules Are Way to Go for Brown


Galapagos Genomics is heading in new directions — under the watch of Robin Brown, who was recently named chief scientific officer of the Belgium-based company.

Brown comes to Galapagos from another small company, Devgen, which looks for validated targets and in vivo active compounds for pharmaceuticals and agrochemical industries. Before that, he spent nine years at Glaxo, where he was the head of the cell and molecular biology department at the Stevenage, UK, research campus.

The move from industry giant to the 80-person Galapagos is quite a change. “In a big company like that, it is hard to make an impact individually,” Brown says. “A smaller company presents more opportunities and you can be involved in more parts of the business.”

He spent part of his career in oncology research. “I still have an oncology interest, but I seem to see much more opportunities in other disease. Oncology is typified by a great deal of interest, but very little success. And it’s a very fragmented market, so it can be very difficult to predict where the next drug is coming from,” Brown says.

Galapagos is currently in the early stages of its drug discovery process and is concentrating on small molecules. “I think there are examples where we would consider biologicals,” says Brown, pointing to rheumatoid arthritis, one area of research at Galapagos, where a biological is one of the best drugs on the market.

“For some considerable time, the market will remain very favorably disposed to small molecules, with only limited opportunities for biologicals,” Brown predicts.

— Amanda Urban

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more